Neurology
-
Randomized Controlled Trial Multicenter Study
Teriflunomide added to interferon-β in relapsing multiple sclerosis: a randomized phase II trial.
To evaluate teriflunomide as add-on therapy to ongoing stable-dosed interferon-β (IFNβ) in patients with relapsing forms of multiple sclerosis (RMS). ⋯ This study provides Class II evidence that teriflunomide, 7 and 14 mg, added to IFNβ, is safe. The T1-Gd lesion burden was significantly reduced with both teriflunomide doses.